Semaglutide leads to significant weight loss in Type 2 diabetes patients

Article by Bruce Sylvester. Patients diagnosed with type 2 diabetes and treated with weekly semaglutide have achieved an average weight loss of almost 10kg, researchers reported on March 2, 2021  in The Lancet. Put in other terms, two-thirds of subjects treated with weekly injections of a 2.4mg semaglutide lost at least 5% of their body weight and achieved significant improvement in […]

Semaglutide reduces excess body fat in people with obesity

In adults with obesity or overweight, weekly treatment with the glucagon-like peptide 1 (GLP1) receptor agonist semaglutide leads to reduced excess body fat and increased lean body mass, according to an industry-sponsored study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting. “Our findings suggest that semaglutide, through body weight loss and improvement of body composition, has the potential […]